Table 2

Trial outcomes of patients randomised to convalescent plasma (CCP) compared with standard of care (SOC)

OutcomeOverallCCPSOCRR*P value
Primary outcome
 Time to two consecutively negative reverse transcriptase-PCR, median (IQR), daysn=136n=69n=67
5.5 (4–8)6 (4–11)4 (4–6)0.196
Secondary outcomes
 Time to symptom resolution among symptomatic patients, median (IQR)n=120n=59n=61
2 (1–4)2 (1–4)2 (1–4)0.772
 Progression to severe/critical disease (oxygen saturation <93% or needing oxygen)n=70n=41n=29
16 (22.9)9 (22.0)7 (24.1)0.91 (0.38 to 2.16)0.830
 Mortalityn=136n=69n=67
18 (13.2)10 (14.5)8 (11.9)0.661
  • *Unadjusted risk ratio.